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Abstract
Breast cancer risk is influenced by rare coding variants in susceptibility genes such as BRCA1 and 
many common, mainly non-coding variants. However, much of the genetic contribution to breast 
cancer risk remains unknown. We report results from a genome-wide association study (GWAS) of 
breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 
13,104 controls of East Asian ancestry1. We identified 65 new loci associated with overall breast 
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cancer at p<5x10-8. The majority of credible risk SNPs in the new loci fall in distal regulatory 
elements, and by integrating in-silico data to predict target genes in breast cells at each locus, we 
demonstrate a strong overlap between candidate target genes and somatic driver genes in breast 
tumours. We also find that heritability of breast cancer due to all SNPs in regulatory features was 
2-5-fold enriched relative to the genome-wide average, with strong enrichment for particular 
transcription factor binding sites. These results provide further insight into genetic susceptibility to 
breast cancer and will improve the utility of genetic risk scores for individualized screening and 
prevention.
We genotyped 61,282 female breast cancer cases and 45,494 female controls of European 
ancestry with the OncoArray1. Subjects came from 68 studies collaborating in the Breast 
Cancer Association Consortium (BCAC) and Discovery, Biology and Risk of Inherited 
Variants in Breast Cancer Consortium (DRIVE) (Supplementary Table 1). Using the 1000 
Genomes Project (Phase 3) reference panel, we imputed genotypes for ˜21M variants. After 
filtering on minor allele frequency (MAF)>0.5% and imputation quality score>0.3 (see 
Online Methods), we assessed the association between breast cancer risk and 11.8M SNPs 
adjusting for country and ancestry-informative principal components. We combined these 
results with results from the iCOGS project (46,785 cases and 42,892 controls)2 and 11 
other breast cancer GWAS (14,910 cases, 17,588 controls), using a fixed-effect meta-
analysis.
Of 102 loci previously associated with breast cancer in Europeans, 49 showed evidence for 
association with overall breast cancer in the OncoArray dataset at P<5x10-8 and 94 at 
P<0.05. Five additional loci previously shown to be associated with breast cancer in Asian 
women also showed evidence in the European ancestry OncoArray dataset (P<0.01; 
Supplementary Tables 2-4)3–5. We also assessed the association with breast cancer in 
Asians including 7,799 cases and 6,480 controls from the OncoArray project and 6,269 
cases and 6,624 controls from iCOGS. Of the 94 loci previously identified in Europeans that 
were polymorphic in Asians, 50 showed evidence of association (P<0.05). For the remaining 
44, none showed a significant difference in the estimated odds ratio (OR) for overall breast 
cancer between Europeans and Asians (P>0.01; Supplementary Table 5). The correlation in 
effect sizes for all known loci between Europeans and Asians was 0.83, suggesting that the 
majority of known susceptibility loci are shared between these populations.
To search for additional susceptibility loci, we assessed all SNPs excluding those within 
500kb of a known susceptibility SNPs (Figure 1). This identified 5,969 variants in 65 
regions that were associated with overall breast cancer risk at P<5x10-8 (Supplementary 
Tables 6-8). For two loci (lead SNPs rs58847541 and rs12628403), there was evidence of a 
second association signal after adjustment for the primary signal (rs13279803: conditional 
P=1.6x10-10; rs373038216: P=2.9x10-11; Supplementary Table 9). Of the 65 new loci, 21 
showed a differential association by ER-status (P<0.05) with all but two (rs6725517 and 
rs6569648) more strongly associated with ER-positive disease (Supplementary Tables 
10-11). Forty-four loci showed evidence of association for ER-negative breast cancer 
(P<0.05). Of the 51 novel loci that were polymorphic in Asians, nine were associated at 
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P<0.05 and only two showed a difference in the estimated OR between Europeans and 
Asians (P<0.01; Supplementary Table 12).
To define a set of credible risk variants (CRVs) at the new loci, we first selected variants 
with P-values within two orders of magnitude of the most significant SNPs in each region. 
Across the 65 novel regions, we identified 2,221 CRVs (Supplementary Table 13), while the 
previous 77 identified loci contained 2,232 CRVs (Online methods; Supplementary Table 
14). We examined the evidence for enrichment in these CRVs of 67 genomic features, 
including histone marks and transcription factor binding sites (TFBS) in three breast cancer 
cell lines (Online Methods; Supplementary Tables 15-16; Extended Data Fig. 1). Thirteen 
features were significant predictors of CRVs at P<10-4; the strongest being DNAse I 
hypersensitivity sites in CTCF silenced MCF7 cells (OR 2.38, P=4.6x10-14). Strong 
associations were also observed with binding sites for FOXA1, ESR1, GATA3, E2F1 and 
TCF7L2. Seven of the 65 novel loci included only a single CRV (Supplementary Table 6), of 
which two are non-synonymous. SNP rs16991615 is a missense variant (p.Glu341Lys) in 
MCM8, involved in genome replication and associated with age at natural menopause and 
impaired DNA repair6. SNP rs35383942 is a missense variant (p.Arg28Gln) in PHLDA3, 
encoding a p53-regulated repressor of AKT7.
We annotated each CRV with publicly available genomic data from breast cells in order to 
highlight potentially functional variants, predict target genes and prioritise future 
experimental validation (Supplementary Tables 7 and 13 with UCSC browser links). We 
developed a heuristic scoring system based on breast-specific genomic data (integrated 
expression quantitative trait and in silico prediction of GWAS targets - INQUISIT) to rank 
the target genes at each locus (Supplementary Table 17). Target genes were predicted by 
combining risk SNP data with multiple sources of genomic information, including 
chromatin interactions (ChIA-PET and Hi-C), computational enhancer-promoter correlations 
(PreSTIGE, IM-PET, FANTOM5 and Super-enhancers), breast tissue-specific eQTL results, 
TF binding (ENCODE ChIP-seq), gene expression (ENCODE RNA-seq) and topologically-
associated domain (TAD) boundaries (Online Methods and Supplementary Tables 18-20). 
Target gene predictions could be made for 58/65 new and 70/77 previously identified loci. 
Among 689 protein-coding genes predicted by INQUISIT, we found strong enrichment for 
established breast cancer drivers identified through tumour sequencing (20/147 genes, 
P<10-6)8–11, which increased with increasing INQUISIT score (P=1.8x10-6). We compared 
INQUISIT with a) an alternative published method (DEPICT, which predicts targets based 
on shared gene functions between potential targets at other associated loci)12 which showed 
a weaker enrichment of breast cancer driver genes (P=0.06 after adjusting for the nearest 
gene, P=0.74 after adjusting for INQUIST score, and b) assigning the association signal to 
the nearest gene, which showed only a weak enrichment of driver genes after adjusting for 
the INQUISIT score (P=0.01; Extended Data Table 1 and Supplementary Table 21). Notably, 
most of the 689 putative target genes have no reported involvement in breast tumorigenesis 
and some may represent additional genes influencing susceptibility to breast cancer. 
However, functional assays will be required to confirm any of these candidates as risk genes.
Having used INQUISIT to predict target genes, we performed pathway gene set enrichment 
analysis (GSEA), visually summarized as enrichment maps (Extended Data Fig. 2; 
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Supplementary Tables 22-23)13. Several growth or development related pathways were 
enriched, notably the fibroblast growth factor, platelet derived growth factor and Wnt 
signalling pathways14–16. Other cancer-related themes included ERK1/2 cascade, immune-
response pathways including interferon signalling, and cell-cycle pathways. Pathways not 
found in earlier breast cancer GWAS include nitric oxide biosynthesis, AP-1 transcription 
factor and NF-kB (Supplementary Table 24).
To explore more globally the genomic features contributing to breast cancer risk, we 
estimated the proportion of genome-wide SNP heritability attributable to 53 publicly 
available annotations17. We observed the largest enrichment in heritability (5.2-fold, 
P=8.5x10-5) for TFBS, followed by a 4-fold (P=0.0006) enrichment for histone marker 
H3K4me3 (marking promoters). In contrast, we observed a significant depletion (0.27, 
P=0.0007) for repressed regions (Supplementary Table 25). We conducted cell type-specific 
enrichment analysis for four histone marks and observed significant enrichments in several 
tissue types (Figure 2; Extended Data Figs. 3-7; Supplementary Table 26-27), including a 
6.7-fold enrichment for H3K4me1 in breast myoepithelial tissue (P=7.9x10-5). We compared 
the cell type-specific enrichments for overall, ER-positive and ER-negative breast cancer to 
the enrichments for 16 other complex traits (Extended Data Figs. 3-7). Breast cancer showed 
enrichment for adipose and epithelial cell types (including breast epithelial cells). In 
contrast, psychiatric diseases showed enrichment specific to central-nervous-system cell 
types and autoimmune disorders showed enrichment for immune cells.
We selected for further evaluation four loci to represent those predicted to act through 
proximal regulation (1p36 and 11p15) and distal regulation (1p34 and 7q22), because they 
had a relatively small number of CRVs. The only CRV at 1p36, rs2992756 (P=1.6x10-15), is 
located 84bp from the transcription start site of KLHDC7A. Of the 19 CRVs at 11p15 
(smallest P=1.4x10-12), five were located in the proximal promoter of PIDD1, implicated in 
DNA-damage-induced apoptosis and tumorigenesis18. INQUIST predicted KLHDC7A and 
PIDD1 to be target genes and they received the highest score for likelihood of promoter 
regulation (Supplementary Table 19). Using reporter assays, we showed that the KLHDC7A 
promoter construct containing the risk T-allele of rs2992756 has significantly lower activity 
than the reference construct, while the PIDD1 promoter construct containing the risk 
haplotype significantly increased PIDD1 promoter activity (Extended Data Fig. 8).
The 1p34 locus included four CRVs (smallest P=9.1x10-9) that fall within two putative 
regulatory elements (PREs) and are predicted by INQUISIT to regulate CITED4 (PREs; 
Extended Data Fig. 8). CITED4 encodes a transcriptional coactivator that interacts with 
CBP/p300 and TFAP2 and can inhibit hypoxia-activated transcription in cancer cells19. 
Chromatin conformation capture (3C) assays confirmed that the PREs physically interacted 
with the CITED4 promoter (Extended Data Fig. 8). Subsequent reporter assays showed that 
the PRE1 reference construct reduced CITED4 promoter activity, whereas the risk T-allele 
of SNP rs4233486 located in PRE1 negates this effect.
Finally, the 7q22 risk locus contained six CRVs (smallest P=5.1x10-12) which lie in several 
PREs spanning ˜40kb of CUX1 intron 1. Chromatin interactions were identified between a 
PRE1 (containing SNP rs6979850) and CUX1/RASA4 promoters and a PRE2 (containing 
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SNP rs71559437) and RASA4/PRKRIP1 promoters (Extended Data Fig. 9). Allele-specific 
3C in heterozygous MBA-MB-231 cells showed that the risk haplotype was associated with 
chromatin looping, suggesting that the protective allele abrogates looping between the PREs 
and target genes (Extended Data Fig. 9). These results identify two mechanisms by which 
CRVs may impact target gene expression: through transactivation of a specific promoter and 
by affecting chromatin looping between regulatory elements and their target genes. These 
data provide in vitro evidence of target identification and regulation, however further studies 
that include genome editing, oncogenic assays and/or animal models will be required to 
fully elucidate disease-related gene function.
We estimate that the newly identified susceptibility loci explain ˜4% of the two-fold familial 
relative risk (FRR) of breast cancer and that in total, common susceptibility variants 
identified through GWAS explain 18% of the FRR. Further, we estimate that variants 
imputable from the OncoArray, under a log-additive model (see Online Methods), explain 
˜41% of the FRR, and thus, the identified susceptibility SNPs account for ˜44% (18%/41%) 
of the FRR that can be explained by all imputable SNPs. The identified SNPs will be 
incorporated into risk prediction models, which can be used to improve the identification of 
women at high and low risk of breast cancer: for example, using a polygenic risk score based 
on the variants identified to date, women in the highest 1% of the distribution have a 3.5-fold 
greater breast cancer risk than the population average. Such risk prediction can inform 
targeted early detection and prevention.
Online Methods
Details of the studies and genotype calling and quality control (QC) for the iCOGS and 
eleven other GWAS are described elsewhere2,20. Seventy-eight studies participated in the 
breast cancer component of the OncoArray, of which 67 studies contributed European 
ancestry data and 12 contributed Asian ancestry data (one study, NBCS, was excluded as 
there were no controls from Norway) (Supplementary Table 1). The majority of studies were 
population-based case-control studies, or case-control studies nested within population-
based cohorts, but a subset of studies oversampled cases with a family history of the disease. 
All studies provided core data on disease status and age at diagnosis/observation, and the 
majority provided additional data on clinico-pathological factors and lifestyle factors, which 
have been curated and incorporated into the BCAC database (version 6). All participating 
studies were approved by their appropriate ethics review board and all subjects provided 
informed consent.
OncoArray SNP Selection
Approximately 50% of the SNPs for the OncoArray were selected as a “GWAS backbone” 
(Illumina HumanCore), which aimed to provide high coverage for the majority of common 
variants through imputation. The remaining SNPs were selected from lists supplied by each 
of six disease-based consortia, together with a seventh list of SNPs of interest to multiple 
disease-focused groups. Approximately 72k SNPs were selected specifically for their 
relevance to breast cancer. These included: (a) SNPs showing evidence of association from 
previous genotype data, based on a combined analysis of eleven existing GWAS together the 
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data from the iCOGS experiment; (b) SNPs showing evidence of association with ER-
negative disease (through a combined analysis with the CIMBA consortium), triple negative 
disease, breast cancer diagnosed before age 40 years, high grade disease, node positive 
disease or ductal carcinoma-in-situ; (c) SNPs potentially associated with breast cancer 
survival; (d) SNPs selected for fine-mapping of 55 regions showing evidence of breast 
cancer association at genome-wide significance; (e) rare variants showing evidence of 
association through exome sequencing in multiple case families, whole-genome sequencing 
in high-risk cases (DRIVE), or analysis of the ExomeChip (BCAC); (f) specific follow-up of 
regions of interest from breast cancer GWAS in Asian, Latina and African/African-
American women; (g) SNPs associated with breast density, selected from GWAS conducted 
by the MODE consortium; (h) breast tissue-specific eQTLs (i) lists of functional candidates 
from >30 groups. Lists were merged with lists from the other consortia as described 
elsewhere1.
OncoArray Calling and QC
Of the 568,712 variants selected for genotyping, 533,631 were successfully manufactured on 
the array (including 778 duplicate probes). Genotyping for the breast cancer component of 
the OncoArray, which included 152,492 samples, was conducted at six sites. Details of the 
genotyping calling for the OncoArray are described in more detail elsewhere1. Briefly, we 
developed a single calling pipeline that was applied to more than 500,000 samples. An initial 
cluster file was generated using data from 56,284 samples, selected to cover all the major 
genotyping centres and ethnicities, using the Gentrain2 algorithm. Variants likely to have 
problematic clusters were selected for manual inspection using the following criteria: call 
rate below 99%, variants with minor allele frequency (MAF)<0.001, poor Illumina intensity 
and clustering metrics, or deviation from the expected frequency as observed in the 1000 
Genomes Project. This resulted in manual adjustment of the cluster file for 3,964 variants, 
and the exclusion of 16,526 variants. The final cluster file was then applied to the full 
dataset.
We excluded probable duplicates and close relatives within each study, and probable 
duplicates across studies. We excluded samples with a call rate <95% or samples with 
extreme heterozygosity (4.89 SD from the mean for the ethnicity). Ancestry was computed 
using a principal component analysis, applied to the full OncoArray dataset, using 2318 
informative markers on a subset of ~47,000 samples. The analysis presented here was 
restricted to women of European ancestry, defined as individuals with an estimated 
proportion of European ancestry >0.8, and women of East Asian ancestry (estimated 
proportion of Asian ancestry >0.4), with reference to the HapMap (v2) populations, based 
on the first two principal components. After quality control exclusions and removing 
overlaps with the previous iCOGS and GWAS genotyping used in the analysis, the final 
dataset comprised data from 61,282 cases and 45,494 of European ancestry 7,799 cases and 
6,480 controls of Asian ancestry.
We excluded SNPs with a call rate <95% in any consortium, SNPs not in Hardy-Weinberg 
equilibrium (P<10-7 in controls or P <10-12 in cases) and SNPs with concordance <98% 
among 5,280 duplicate sample pairs. For the imputation, we additionally excluded SNPs 
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with a MAF<1% and a call rate <98% in any consortium, SNPs that could not be linked to 
the 1000 Genomes Project reference or differed significantly in frequency from the 1000 
Genomes Project dataset (using the criterion  where p0 and 
p1 are the MAFs in the 1000 Genomes Project and OncoArray European datasets, 
respectively). A further 1,128 SNPs where the cluster plot was judged to be not ideal on 
visual inspection were excluded. Of the 533,631 SNPs that were manufactured on the array, 
494,763 SNPs passed the initial QC and 469,364 SNPs were used in the imputation.
Genotype Imputation
All samples were imputed using the October 2014 (version 3) release of the 1000 Genomes 
Project dataset as the reference panel and number of sampled haplotypes per individual 
(Nhap)=800. The iCOGS, OncoArray and nine of the GWAS datasets were imputed using a 
two-stage imputation approach, using SHAPEIT2 for phasing and IMPUTEv2 for 
imputation21,22. The imputation was performed in 5Mb non-overlapping intervals. The 
subjects were split into subsets of ~10,000 samples; where possible subjects from the same 
study were included in the same subset. The BPC3 and EBCG studies were imputed 
separately using MACH and Minimac23,24. 99.6% of SNPs with frequency >1% were 
imputable with r2>0.3 in the OncoArray dataset and 99.1% in the iCOGS dataset. We 
generated estimated genotypes for all SNPs that were polymorphic (MAF>0.1%) in either 
European or Asian samples (˜21M SNPs). For the current analysis, however, we restricted to 
SNPs with MAF>0.5% in the European OncoArray dataset (11.8M SNPs). One-step 
imputation (without pre-phasing) was performed, on the iCOGS and OncoArray datasets, as 
a quality control step for those associated loci where the imputation quality score was <0.9. 
Imputation quality for the lead variants, as assessed by the IMPUTE2 quality score in the 
OncoArray dataset, was >0.80 for all but one locus (Supplementary Table 28) rs72749841, 
quality score=0.65).
Principal Components Analysis
To adjust for potential (intra-continental) population stratification in the OncoArray dataset, 
principal components analysis was performed using data from 33,661 uncorrelated SNPs 
(which included 2,318 SNPs specifically selected on informativeness for determining 
continental ancestry) with a MAF of at least 0.05 and maximum correlation of 0.1 in the 
OncoArray dataset, using purpose-written software (http://ccge.medschl.cam.ac.uk/software/
pccalc). For the main analyses, we used the first ten principal components, as additional 
components did not further reduce inflation in the test statistics. We used nine principal 
components for the iCOGS and up to ten principal components for the other GWAS, where 
this was found to reduce inflation.
Statistical Analyses
Per-allele ORs and standard errors were generated for the OncoArray, iCOGS and each 
GWAS, adjusting for principal components using logistic regression. The OncoArray and 
iCOGS analyses were additionally adjusted for country and study, respectively. For the 
OncoArray analysis, we adjusted for country and 10 principal components. Adjustment for 
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country rather than study was used to improve power since some studies had no few or no 
controls. We evaluated the adequacy of this approach by comparing the inflation in the test 
statistic with that obtained in corresponding analysis in which we adjusted for study – the 
inflation was very similar (λ=1.15 vs. 1.17, based on the backbone SNPs, equivalent to 
λ1000=1.003, for a study of 1,000 cases and 1,000 controls, in both cases). As an additional 
sensitivity analysis, we computed the effect sizes for the 65 novel loci adjusting for study – 
the effect sizes were essentially identical to those presented. Estimates were derived using 
ProbAbel for the BPC3 and EBCG studies25, SNPTEST for the remaining GWAS and 
purpose written software for the iCOGS and OncoArray datasets. OR estimates and standard 
errors were combined in a fixed effects inverse variance meta-analysis using METAL26, 
adjusting the GWAS (but not iCOGS or OncoArray) results for genomic control as described 
previously2. For the GWAS, results were included in the analysis for all SNPs with 
MAF>0.01 and imputation r2>0.3. For iCOGS and OncoArray we included all SNPs with 
r2>=0.3 and MAF>0.005 (11.8M SNPs in total). We viewed the primary tests of association 
as those based on all the meta-analysis over all stages, as this has been shown to be powerful 
than tests based on a test-replication approach27. Eight sets of variants were associated with 
breast cancer at P<5x10-8 but were close to previous susceptibility regions, and these 
became non-significant after adjustment for the previously identified lead variant. Two SNPs 
on 22q13.2, rs141447235 and rs73161324, were both associated with overall breast cancer 
but, despite lying >500kb apart, were strongly correlated with each other (r2=0.50) and 
hence were considered as a single novel signal.
For SNPs showing evidence of association, we additionally computed genotype-specific 
ORs for the iCOGS and OncoArray dataset, and per-allele ORs for ER-negative and ER-
positive disease. Departures from a log-additive model were evaluated using a one degree of 
freedom likelihood ratio test, comparing the log-additive model (genotypes parametrised as 
the number of rare alleles carried) with the general model estimating ORs for each genotype. 
The genotype-specific risks for all variants were consistent with a log-additive model 
(P>0.01; Supplementary Table 29). Tests for differences in the OR by ER-status were 
derived using case-only analyses, in which estimates were derived by logistic regression 
separately in the iCOGS and OncoArray datasets, adjusted as before, and then combined in a 
fixed-effects meta-analysis. These analyses were performed in R28.
We assessed heterogeneity in the OR estimates among studies within each of the OncoArray, 
iCOGS and GWAS components, and between the (combined) estimates for the three 
components, using both the I2 statistic and the P-value for Cochran’s Q statistic 
(Supplementary Table 28). There was no evidence of heterogeneity among studies in the 
ORs for any of the loci in the OncoArray, but three loci showed some evidence of 
heterogeneity in the ORs among the GWAS, iCOGS and OncoArray datasets.
To determine whether there were multiple independent signals in a given region, we 
performed multiple logistic regression analysis using SNPs within 500kb of each lead SNP, 
adjusting for the lead SNP. We used the genotypes derived by one-step imputation, 
performed the analyses separately in the iCOGS and Oncoarray datasets and combined the 
results (adjusted effect sizes and standard errors) using a fixed effects meta-analysis. For one 
of the two loci for which there was an additional signal significant at P<5x10-8, the lead 
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SNP from the one-step imputation differed from the lead SNP in the overall analysis, but 
was strongly correlated with it (Supplementary Table 9).
Definition of Known Hits
We attempted to identify all associations previously reported from genome-wide or 
candidate analysis at a significance level P<5x10-8 for overall breast cancer, ER-negative or 
ER-positive breast cancer, in BRCA1 or BRCA2 carriers, or in meta-analyses of these 
categories. Where multiple studies reported associations in the same region, we used the first 
reported association unless later studies identified a variant that was clearly more strongly 
associated. We only included one SNP per 500kb interval, unless joint analysis provided 
clear evidence (P<5x10-8) of more than one independent signal. For the analysis of credible 
risk variants (CRVs), we restricted attention to regions where the most significant signal had 
a P-value<10-7 in Europeans (77 regions). To avoid complications with defining CRVs for 
secondary signals, we considered only the primary signal and defined CRVs as those whose 
P-value was within two orders of magnitude of the most significant P-value.
In-Silico Analysis of CRVs
We combined multiple sources of in silico functional annotation from public databases to 
help identify potential functional SNPs and target genes. To investigate functional elements 
enriched across the region encompassing the strongest CRVs, we analysed chromatin 
biofeatures data from the Encyclopedia of DNA Elements (ENCODE) Project29, Roadmap 
Epigenomics Projects30 and other data obtained through the National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) namely: Chromatin 
State Segmentation by Hidden Markov Models (chromHMM), DNase I hypersensitive and 
histone modifications of epigenetic markers H3K4, H3K9, and H3K27 in Human Mammary 
Epithelial (HMEC) and myoepithelial (MYO) cells, T47D and MCF7 breast cancer cells and 
TF ChIP-seq in a range of breast cell lines (Supplementary Table 13).
Association of Genomic Features with CRVs
We first defined credible candidate variants as those located within 500kb of the most 
significant SNP in each region, and with P-values within two orders of magnitude of the 
most significant SNPs. This is approximately equivalent to flagging variants whose posterior 
probability of causality is within two orders of magnitude of that of the most significant 
SNP31,32. We then selected 800 random 1Mb control regions separated by at least 1Mb 
from each other and from the intervals defined by the associated SNPs. The association with 
each feature was then evaluated using logistic regression, with being a CRV as the outcome, 
and adjusting for the dependence due to linkage disequilibrium using robust variance 
estimation, clustering on region, using the R package multiwayvcov.
eQTL analyses
Expression QTL analyses were performed using data from The Cancer Genome Atlas 
(TCGA) and Molecular Taxonomy of Breast Cancer International Consortium 
(METABRIC) projects9,33. The TCGA eQTL analysis was based on 458 breast tumours 
that had matched gene expression, copy number, and methylation profiles together with the 
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corresponding germline genotypes available. All 458 individuals were of European ancestry 
as ascertained using the genotype data and the Local Ancestry in adMixed Populations 
(LAMP) software package (LAMP estimate cut-off >95% European)34. Germline genotypes 
were imputed into the 1000 Genomes Project reference panel (October 2014 release) using 
IMPUTE223,35. Gene expression had been measured on the Illumina HiSeq 2000 RNA-Seq 
platform (gene-level RSEM normalized counts36), copy number estimates were derived 
from the Affymetrix SNP 6.0 (somatic copy number alteration minus germline copy number 
variation called using the GISTIC2 algorithm37), and methylation beta values measured on 
the Illumina Infinium HumanMethylation450. Expression QTL analysis focused on all 
variants within 500 kb of the most significantly associated risk SNP in 142 genomic regions 
(each 2-Mb wide) containing at least one previously identified or new overall breast cancer 
risk locus confirmed at genome-wide significance in the current meta-analysis. Each variant 
was evaluated for its association with the expression of every gene within 2 Mb that had 
been profiled for each of the three data types. The effects of tumour copy number and 
methylation on gene expression were first regressed out using a method described 
previously38. eQTL analysis was performed by linear regression, with residual gene 
expression as outcome, germline SNP genotype dosage as the covariate of interest and ESR1 
expression and age as additional covariates, using the R package Matrix eQTL39.
The METABRIC eQTL analysis was based on 138 normal breast tissue samples resected 
from breast cancer patients of European ancestry. Germline genotyping for the METABRIC 
study was also done on the Affymetrix SNP 6.0 array, and gene expression in the 
METABRIC study was measured using the Illumina HT12 microarray platform (probe-level 
estimates). No adjustment was implemented for somatic copy number and methylation status 
since we were evaluating eQTLs in normal breast tissue. All other steps were identical to the 
TCGA eQTL analysis described above.
INQUISIT
We developed a computational pipeline, integrated expression quantitative trait and in silico 
prediction of GWAS targets (INQUISIT), to interrogate publically available data for the 
prioritisation of candidate target genes.
Data used for INQUISIT—Chromatin interaction data from ENCODE ChIA-PET 
analysis in MCF-7 cells for RNApolII, ERalpha, and CTCF factors were downloaded using 
UCSC Table Browser40. Hi-C data derived from HMECs were obtained from Rao et al.41, 
using “interaction loops” as defined in the publication. Data were reformatted to facilitate 
intersection of query SNPs using BEDTools “intersect”42. For all interactions, termini were 
intersected with promoters using GENCODE v1943 Basic gene annotations, where we 
defined promoters as -1.0 kb - +0.1 kb surrounding a transcription start site.
Enhancer-target gene predictions by several computational algorithms were collected. Each 
of these datasets assigns genes to enhancers. We used all MCF-7 and HMEC enhancer 
predictions (low and high stringency) made by PreSTIGE44, IM-PET enhancer-gene 
predictions in MCF-7, HMEC and HCC1954 cell lines45. Enhancer-transcription start site 
(E-TSS) links were identified from the FANTOM5 Consortium were identified46, and 
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enhancers detected in mammary epithelial cells were intersected with E-TSS links. We also 
collected typical and super-enhancers in MCF-7, HMEC and HCC1954 cells defined by 
Hnisz et al.47.
TF ChIP-seq peak data for ESR1, FOXA1, GATA3, TCF7L2 and E2F1 from MCF-7, T47D 
and MCF-10A cells were downloaded in narrowPeak format from ENCODE. H3K4me3 and 
H3K9ac (characteristic of promoters) histone modification ChIP-seq peak data for all breast 
cells were obtained from ENCODE and Roadmap Epigenomics Project. ChromHMM data 
for breast cell samples (HMEC and myoepithelial: E027, E028 and E119) were downloaded 
from Roadmap Epigenomics.
Expression QTL analyses were conducted as described above. In the interpretation of the 
eQTL results for INQUISIT (and in general) we focused on the overlap between the CRVs 
(risk signal) and the top eQTL variants for a given gene (eQTL signal). If the eQTL P-value 
for a CRV was the same as, or within 1/100th of the eQTL P-value of the SNP most 
significantly associated with expression of a particular gene, that gene and the corresponding 
CRV were assigned a point for being an eQTL in INQUISIT.
Topologically-associated domain (TAD) boundaries were derived from Hi-C data41. 
Genomic intervals corresponding to “contact domains” from eight human cell types were 
merged using BEDTools “merge” resulting in annotation of regions most likely to 
encompass TAD units. Inter-TAD boundaries were identified using BEDTools 
“complement”.
Gene level RNA-seq expression data generated under multiple experimental conditions in 
MCF-7 and normal mammary epithelial cells were downloaded from ENCODE. The FPKM 
(Fragments Per Kilobase of exon per Million fragments Mapped) values for each gene were 
extracted using the metagene R package48 and averaged across all experiments to give an 
approximation of expression in breast cells. Accession numbers are given in Supplementary 
Table 30.
INQUISIT pipeline
Candidate target genes were evaluated by assessing each CRV’s potential impact on 
regulatory or coding features. Scores categorised by 1) distal gene regulation, 2) proximal 
gene regulation, or 3) impact on protein coding were calculated using the following criteria 
(see also Supplementary Table 17).
Genomic annotation data for target gene predictions (chromatin interaction and 
computational enhancer-promoter assignment), ChIP-seq, histone modification, and 
chromHMM were curated into a BED formatted database. We intersected the chromosomal 
positions of CRVs with each category of genomic annotation data using BEDTools 
“intersect” (minimum 1 bp overlap), resulting in annotation of SNP-gene pairs with presence 
or absence of multiple classes of genomic data. Each gene was scored using a custom R 
script on the basis of the following criteria:
- For distally regulated genes, a candidate gene was given 2 points if a CRV fell in 
an element that revealed long range ChIA-PET or Hi-C interactions with that 
Michailidou et al. Page 11
Nature. Author manuscript; available in PMC 2018 April 23.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
gene’s promoter. One point was added to a gene's score in the case of enhancers 
predicted by computational methods to target that gene (in addition to 
experimental interactions if also observed). If the distal elements harbouring 
SNPs also overlapped enriched cistromic TF (ESR1, FOXA1, GATA3, TCF7L2, 
E2F1) ChIP-seq peaks, an additional point was given when one SNP-Enhancer-
ChIP-seq peak intersection occurred, but two points when there were multiple 
TF binding sites overlapping SNPs in distinct interactions or enhancers (see 
Supplementary Table 17 for details). One point was given to significant eSNP-
eGENE pairs. Predicted distal target genes which were among the list of breast 
cancer driver genes were up-weighted with a further point (except for the 
analysis of driver gene enrichment). Information regarding TAD boundaries was 
used to down-weight genes: genes which were separated from CRVs by a TAD 
boundary were down-weighted by multiplying their scores by 0.05. Scores for 
genes exhibiting no expression in MCF7 or HMEC (mean FPKM = 0) were 
multiplied by 0.1. This resulted in scores for each candidate target gene ranging 
from 0 to 8.
- Variants were treated as potentially affecting proximal promoter regulation if 
they resided between -1.0 and +0.1 kb surrounding a transcription start site. 
Additional points was awarded to genes when variants overlapped promoter 
H3K4me3 or H3K9ac histone modification peaks, intersected with ESR1, 
FOXA1, GATA3, TCF7L2 or E2F1 TF binding sites, were significant eSNP-
eGENE pairs, and if the gene was annotated as a breast cancer driver gene. Gene 
scores were down-weighted (by a factor of 0.1) if they lacked expression in 
MCF-7 or HMEC samples. Resultant scores ranged from 0 to 5.
- Intragenic variants were evaluated for their potential to impact protein function 
using a range of in silico prediction tools (CADD49, FATHMM50, LRT51, 
MutationAssessor52, Mutation Taster 253, PolyPhen-254, PROVEAN55 and 
SIFT56 for missense variants; Human Splicing Finder57 and MaxEntScan58 for 
splice variants). We scored genes with missense and nonsense variants predicted 
to be functionally deleterious, and points for genes harbouring variants predicted 
to alter splicing. Genes could therefore carry SNPs which affect coding and 
splicing and receive increased scores. Additional points were given to genes 
which were breast cancer driver genes. We multiplied scores by 0.1 when genes 
showed a lack of expression in breast cells. Possible coding scores ranged from 
0-4.
Enrichment of Somatic Breast Cancer Driver Genes in INQUISIT Target Gene Predictions
We listed 147 unique protein coding driver genes for breast cancer identified from four 
recent tumour genome and exome sequencing studies (considering ZNF703 and FGFR1 as 
independent genes; Supplementary Table 31)8–11. First, we examined overlap between this 
list of 147 genes and the total set of unique target genes predicted by INQUISIT (n = 689) 
by one or more of the three regulatory mechanisms (distal, promoter, and coding). The 
significance of this overlap was assessed by randomly drawing (without replacement) 689 
genes from the set of all protein coding genes (GENCODE release 19, n = 20,243) one 
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million times and calculating the probability of observing the same (or stronger) overlap 
with the list of 147 drivers. Second, we hypothesised that this enrichment would be stronger 
with progressively higher INQUISIT scores. We categorised all 20,243 protein coding genes 
into four levels based on their INQUIST scores (level 1: coding score 2, promoter score 3-4, 
distal score >4; level 2: coding 1, promoter 1-2, distal 1-4; level 3: any score >0 but <1; level 
4: score 0 i.e. not a predicted target). The gene nearest to a risk locus is frequently assigned 
as a candidate target gene in GWAS in the absence of additional functional analysis59. We 
observed that seven of the 147 drivers were among the genes nearest to a previously or 
newly identified breast cancer risk locus. Therefore, we used logistic regression, including 
data for all target genes predicted by INQUISIT, with driver status as outcome, and 
evaluated INQUISIT score level and nearest gene status as potential predictors of driver 
status (Supplementary Table 21).
Lead SNPs at 142 breast cancer risk associated loci were used as input into DEPICT which 
was then run using the default settings12. We examined the relative performance of 
INQUISIT and DEPICT in predicting driver gene status using logistic regression models as 
above (Supplementary Table 21), adding DEPICT prediction as a covariate.
Chromatin Conformation Capture (3C)
MCF7 (ATCC #HTB22) and MDA-MB-231 (ATCC #HTB26) breast cancer cell lines were 
grown in RPMI medium with 10% FCS and antibiotics. Bre-80 normal breast epithelial cells 
(provided as a gift from Roger Reddel, CMRI, Sydney) were grown in DMEM/F12 medium 
with 5% horse serum (HS), 10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 20 ng/ml epidermal 
growth factor, 100 ng/ml cholera toxin and antibiotics. Cell lines were maintained under 
standard conditions, routinely tested for Mycoplasma and short tandem repeat (STR) 
profiled to confirm cell line identity. 3C libraries were generated using EcoRI as described 
previously60. 3C interactions were quantitated by real-time PCR (qPCR) using primers 
designed within restriction fragments (Supplementary Table 32). qPCR was performed on a 
RotorGene 6000 using MyTaq HS DNA polymerase (Bioline) with the addition of 5 mM of 
Syto9, annealing temperature of 66°C and extension of 30 sec. 3C analyses were performed 
in three independent 3C libraries from each cell line with each experiment quantified in 
duplicate. BAC clones covering each region were used to create artificial libraries of ligation 
products in order to normalize for PCR efficiency. Data were normalized to the signal from 
the BAC clone library and, between cell lines, by reference to a region within GAPDH. All 
qPCR products were electrophoresed on 2% agarose gels, gel purified and sequenced to 
verify the 3C product.
Plasmid Construction and Reporter Assays
Promoter-driven luciferase reporter constructs were generated by insertion of PCR amplified 
fragments or synthesised gBlocks (Integrated DNA Technologies) containing the 
KLHDC7A, PIDD1 or CITED4 promoters into the KpnI/HindIII sites of pGL3-Basic. For 
the 1p34 locus, a 1169 bp putative regulatory element (PRE1) or 951 bp PRE2 were 
synthesised as gBlocks and cloned into the BamHI/SalI sites of the CITED4-promoter 
construct. The minor alleles of SNPs were introduced into promoter or PRE sequences by 
overlap extension PCR or gBlocks. Sequencing of all constructs confirmed variant 
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incorporation (AGRF). MCF7 or Bre-80 cells were transfected with equimolar amounts of 
luciferase reporter plasmids and 50 ng of pRLTK transfection control plasmid with 
Lipofectamine 2000. The total amount of transfected DNA was kept constant at 600 ng for 
each construct by the addition of pUC19 as a carrier plasmid. Luciferase activity was 
measured 24 hr posttransfection by the Dual-Glo Luciferase Assay System. To correct for 
any differences in transfection efficiency or cell lysate preparation, Firefly luciferase activity 
was normalized to Renilla luciferase, and the activity of each construct was measured 
relative to the reference promoter constructs, which had a defined activity of 1. Statistical 
significance was tested by log transforming the data and performing 2-way ANOVA, 
followed by Dunnett’s multiple comparisons test in GraphPad Prism.
Global Genomic Enrichment Analyses
We performed stratified LD score regression analyses17 for overall breast cancer as well as 
stratified by ER status using the summary statistics based on the meta-analyses of the 
OncoArray, GWAS and iCOGS datasets. We restricted analysis to all SNPs present on the 
HapMap version 3 dataset that had a MAF > 1% and an imputation quality score R2>0.3 in 
the OncoArray data. LD scores were calculated using the 1000 Genomes Project Phase 3 
EUR reference panel.
We first created a “full baseline model” as previously described that included 24 non-cell 
type specific publicly available annotations as well as 24 additional annotations that 
included a 500-bp window around each of the 24 main annotations17. Additionally, we also 
included 100-bp windows around ChIP-seq peaks as well as one annotation containing all 
SNPs leading to a total of 53 overlapping annotations.
We subsequently performed analyses using cell-type specific annotations for four histone 
marks H3K4me1, H3K4me3, H3K9ac and H3K27ac across 27-81 cell types depending on 
histone mark17. Each cell-type-specific annotation corresponded to a histone mark in a 
single cell type, and there were 220 such annotations in total. We augmented the baseline 
model by adding these annotations individually, creating 220 separate models, each with 54 
annotations (53+1). This procedure controls for the overlap with the 53 functional categories 
in the full baseline model but not with the 219 other cell type specific annotations.
We further tested the differences in functional enrichment between ER-positive and ER-
negative subsets through a Wald test, using the regression coefficients and standard errors for 
the two subsets based on the models described above.
Contribution of Identified Variants to the Familial Relative Risk of Breast Cancer
We estimated the proportion of the familial risk of breast cancer due to the identified 
variants, under a log-additive model, using the formula: 
where pi is the MAF for variant i, βi is the log(OR) estimate for variant i, τi is the standard 
error of βi and λ=2 is the assumed overall familial relative risk.
To compute the corresponding estimate for the FRR due to all variants, we wish to estimate 
 where the sum is now over the all variants and βi is the true relative 
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risk conferred by variant i, assuming a log-additive model. We refer to  as the frailty scale 
heritability. We first obtained the estimated observed heritability based on the full set of 
summary estimates using LD Score Regression17 and then converted this to an estimate on 
the frailty scale using the  where P is the proportion of samples in the 
population that are cases.
Pathway Analyses
The pathway gene set database (http://download.baderlab.org/EM_Genesets, file 
Human_GOBP_AllPathways_no_GO_iea_April_01_2017_symbol.gmt)13 from the Bader 
lab dated April 1, 2017 was used in all analyses. This database contains pathways from 
Reactome61, NCI Pathway Interaction Database62, GO (Gene Ontology) biological 
process63, HumanCyc64, MSigdb65, NetPath66 and Panther67. For GO, terms inferred 
from electronic annotation were excluded from our analyses. The same pathway may be 
defined in two or more databases with potentially different sets of genes. All versions of 
such ‘duplicate’ pathways were included. To provide more biologically meaningful results 
and reduce false positives, only pathways that contained between 10 and 200 genes were 
used. Pathway size was determined by the total number of genes in the pathway that could 
also be mapped to the genes included in the GWAS dataset (actual pathway size may be 
larger).
SNPs were assigned to genes using the INQUISIT target prediction method described above 
for all SNPs with P-value < 5x10-2 (˜1.25 million associations). This cutoff was chosen 
based on a threshold analysis that showed that 19 of the 20 pathway themes found using all 
SNP associations (˜16 million) and a simple distance-based SNP-to-gene mapping method 
could be recovered using this smaller subset of associations. More stringent cutoffs resulted 
in fewer themes being covered (e.g. three themes found using SNPs with p-value < 5x10-6 or 
˜33K SNP associations). Gene significance was calculated by assigning the statistic of the 
most significant SNP among all SNPs assigned to a gene68,69. Since histone genes 
contained a high number of mapped SNPs, we selected representative SNP associations to 
avoid pathway enrichments based solely on the increased number of SNPs at these loci (i.e. 
chr6:27657944 for HIST1, chr1:149219841, for HIST2, chr1: 228517406 for HIST3, chr12: 
14871747 for HIST4).
The gene set enrichment analysis (GSEA) algorithm as implemented in the GenGen 
package69 was used to perform pathway analysis. Wang et al.70 modified the original 
GSEA algorithm to work with GWAS datasets, using SNP significance and SNP-to-gene 
mapping instead of gene expression data. Briefly, the algorithm calculates an enrichment 
score (ES) for each pathway based on a weighted Kolmogorov-Smirnov statistic (refer to 70 
for more details). Pathways that have most of their genes at the top of the ranked list of 
genes obtain higher ES values. Note that only the largest positive ES was considered as 
opposed to largest absolute ES (i.e. largest deviation from zero). This modification 
(recommended by the GenGen authors for GWAS analysis) was performed to include only 
pathways that are significantly affected between cases and controls and ignore those with 
significant negative ES values (this may happen if a pathway is significantly less altered than 
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expected by chance). Only pathways containing greater than 10 genes with at least one of 
these genes with P-value < 5x10-8 were retained as higher confidence for subsequent 
analysis. These pathways, together with the genes reaching the significance threshold, are 
listed in Supplementary Table 22.
The pathway analysis assigns an enrichment score (ES) value for each pathway. These 
values were normalized and p-values for each pathway were obtained by comparing them to 
null distributions for OncoArray and iCOGS data sets separately. The null distributions were 
computed by permuting case/control labels 1,000 times (keeping the number of cases and 
controls the same in each iteration) and recomputing all enrichment statistics. FDR values 
were computed using the statistics from the null distributions and all pathways with FDR < 
0.05 in either OncoArray or iCOGS distributions were considered further. Pathway findings 
were further considered if they contained more than one significant gene and if they could be 
confirmed to be involved in breast cancer as reported in at least one of five published large-
scale breast cancer GWAS71–75 or reported elsewhere in the literature. Further, themes that 
were weakly associated with breast cancer (based on a literature search) were only included 
if they had a FDR < 0.05 and at least four novel genes (i.e. was not found among the genes 
from mapped themes containing pathways known to be involved in breast cancer) (Extended 
Data Fig. 2). Pathways related to “sensory perception of smell” were removed as there is no 
literature evidence for their involvement in breast cancer and because they contain genes 
close to each other on chromosome 6 which are frequently correlated.
An enrichment map was created using the Enrichment Map (EM) v 2.1.0 app13 in 
Cytoscape v 3.376. Pathways nodes were laid out using a force directed layout and nodes 
with gene set overlap of over 0.55 were connected by edges. Related pathway nodes were 
manually clustered and labelled as themes.
Data Availability
A subset of the data that support the findings of this study is publically available via dbGaP 
(www.ncbi.nlm.nih.gov/gap; accession number phs001265.v1.p1). The complete dataset will 
not be made publicly available due to restraints imposed by the ethics committees of 
individual studies; requests for data can be made to the corresponding author or the Data 
Access Coordination Committee (DACCs) of BCAC (http://bcac.ccge.medschl.cam.ac.uk/): 
BCAC DACC approval is required to access data from studies ABCFS, ABCS, ABCTB, 
BBCC, BBCS, BCEES, BCFR-NY, BCFR-PA, BCFR-UT, BCINIS, BSUCH, CBCS, 
CECILE, CGPS, CTS, DIETCOMPLYF, ESTHER, GC-HBOC, GENICA, GEPARSIXTO, 
GESBC, HABCS, HCSC, HEBCS, HMBCS, HUBCS, KARBAC, KBCP, LMBC, MABCS, 
MARIE, MBCSG, MCBCS, MISS, MMHS, MTLGEBCS, NC-BCFR, OFBCR, ORIGO, 
pKARMA, POSH, PREFACE, RBCS, SKKDKFZS, SUCCESSB, SUCCESSC, SZBCS, 
TNBCC, UCIBCS, UKBGS and UKOPS (see Supplementary Table 1).
Summary results for all variants are available at http://bcac.ccge.medschl.cam.ac.uk/. 
Requests for further data should be made through the BCAC Data Access Co-ordinating 
Committee (http://bcac.ccge.medschl.cam.ac.uk/).
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Extended Data
Extended data Figure 1. Global mapping of biofeatures across novel loci associated with overall 
breast cancer risk.
The overlaps between potential genomic predictors in relevant breast cell lines and candidate 
causal risk variants (CRVs) within each locus. On the x-axis, each column represents a CRV 
(see Online Methods). The most significant SNPs are identified in each region. On the y-
axis, biofeatures are grouped into five functional categories: genomic structure (red), 
enhancer marks (dark green), histone marks (blue), open chromatin marks (dark blue) and 
transcription factor binding sites (dark violet). Colored elements indicate SNPs for which the 
feature is present. For data sources, see Online Methods (“In-Silico Analysis of CRVs”).
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Extended data Figure 2. Pathway enrichment map for susceptibility loci based on summary 
association statistics.
Each circle (node) represents a pathway (gene set), coloured by enrichment score (ES) 
where redder nodes indicate lower FDRs. Larger nodes indicate pathways with more genes. 
Green lines connect pathways with overlapping genes (minimum overlap 0.55). Pathways 
are grouped by similarity and organized into major themes (large labelled circles).
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Extended data Figure 3. Heatmap showing patterns of cell type-specific enrichments for breast 
tissue across three histone marks (H3K4me1, H3K4me3 and H3K9ac) for breast cancer overall, 
ER-positive breast cancer and ER-negative breast cancer as well as 16 other traits.
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Extended data Figure 4. Heatmap showing patterns of cell type-specific enrichments for histone 
mark H3K27ac in breast cancer overall, ER+ and ER- breast cancer as well as 16 other traits.
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Extended data Figure 5. Heatmap showing patterns of cell type-specific enrichments for histone 
mark H3K4me1 in breast cancer overall, ER+ and ER- breast cancer as well as 16 other traits.
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Extended data Figure 6. Heatmap showing patterns of cell type-specific enrichments for histone 
mark H3K4me3 in breast cancer overall, ER+ and ER- breast cancer as well as 16 other traits.
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Extended data Figure 7. Heatmap showing patterns of cell type-specific enrichments for histone 
mark H3K9ac in breast cancer overall, ER-positive and ER-negative breast cancer as well as 16 
other traits.
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Extended data Figure 8. Functional assessment of regulatory variants at 1p36, 11p15 and 1p34 
risk loci.
a, The KLHDC7A or b, PIDD1 promoter regions containing the reference (prom-Ref) or 
risk alleles (prom-Hap), were cloned upstream of the pGL3 luciferase reporter gene. MCF7 
or Bre-80 cells were transfected with constructs and assayed for luciferase activity after 24 
h. Error bars denote 95% CI (n=3). P-values were determined by two-way ANOVA followed 
by Dunnett’s multiple comparisons test (*P<0.05, **P<0.01, ***P<0.001). c, 3C assays. A 
physical map of the region interrogated by 3C is shown first. Grey boxes depict the putative 
regulatory elements (PREs), blue vertical lines indicate the risk-associated SNPs and black 
dotted line represents chromatin looping. The graphs represent three independent 3C 
interaction profiles. 3C libraries were generated with EcoRI, grey vertical boxes indicate the 
interacting restriction fragment (containing PRE1 and PRE2). Error bars denote SD. d, 
PRE1 or PRE2 containing the reference (PRE-ref) or risk (PRE-Hap) haplotypes were 
cloned downstream of a CITED4 promoter-driven luciferase construct (CITED4 prom). 
MCF7 or Bre-80 cells were transfected with constructs and assayed for luciferase activity 
after 24 h. Error bars denote 95% CI (n=3). P-values were determined by two-way ANOVA 
followed by Dunnett’s multiple comparisons test (**P<0.01, ***P<0.001).
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Extended data Figure 9. Functional assessment of regulatory variants at the 7q22 risk locus.
a-e, 3C assays. A physical map of the region interrogated by 3C is shown first. Grey 
horizontal boxes depict the putative regulatory elements (PREs), blue vertical lines indicate 
the risk-associated SNPs and black dotted line represents chromatin looping. The graphs 
represent three independent 3C interaction profiles between the a, CUX1, b, d, PRKRIP1 or 
c, e, RASA4 promoter regions and PREs. 3C libraries were generated with EcoRI, grey 
vertical boxes indicate the interacting restriction fragment (containing PRE1 and/or PRE2). 
Error bars denote SD. f, g, Allele-specific 3C. 3C followed by Sanger sequencing for the f, 
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PRKRIP1-PRE2 or g, RASA4-PRE1 or -PRE2 in heterozygous MDA-MB-231 breast 
cancer cells.
Extended Data Table 1
INQUISIT, DEPICT, and nearest gene as predictors of 
driver status.
Scores converted into levels for analysis. For INQUISIT: level 1 (coding score of 2 OR 
promoter score of 3 or 4 OR distal score > 4), level 2 (coding score of 1 OR promoter of 1 or 
2 OR distal score of 1, 2, 3, or 4), level 3 (coding/promoter/distal scores > 0 but < 1), and 
level 4 (not predicted to be a target gene by INQUISIT). For DEPICT: level 1 (DEPICT 
predicted target gene at P ≤ 0.05), level 2 (DEPICT predicted target gene but with P > 0.05), 
level 3 (not predicted to be a target gene by DEPICT).
Variable Coefficient Standard Error Z-value P-value
Multivariable logistic regression model with INQUISIT, DEPICT, Nearest gene
INQUISIT -0.61 0.14 -4.31 1.6E-05
DEPICT -0.17 0.50 -0.33 0.74
Nearest gene 1.12 0.59 1.88 0.06
Multivariable logistic regression model with INQUISIT and Nearest gene
INQUISIT -0.63 0.13 -4.77 1.8E-06
Nearest gene 1.23 0.48 2.56 0.01
Multivariable logistic regression model with DEPICT and Nearest gene
DEPICT -0.89 0.49 -1.82 0.07
Nearest gene 1.61 0.63 2.57 0.01
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Figure 1. 
(a) Manhattan plot showing log10P-values for SNP associations with overall breast cancer 
(b) Manhattan plot after excluding previously identified associated regions. The red line 
denotes “genome-wide” significance (P<5x10-8); the blue line denotes P<10-5.
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